Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F.
Poels KE, et al. Among authors: chakrabarti s.
Nat Commun. 2021 Jun 17;12(1):3697. doi: 10.1038/s41467-021-23912-4.
Nat Commun. 2021.
PMID: 34140482
Free PMC article.
Clinical Trial.